For decades, the pharmaceutical industry operated under a predictable, if somewhat rigid, lifecycle model. A new drug would emerge from the R&D pipeline, enjoy a period of high-margin patent protection, and then, upon reaching the “patent cliff,” settle into a state of managed decline. Often referred to as "legacy" or "mature" brands, these assets were treated as steady cash-flow generators—entities requiring minimal investment and even less strategic innovation.
However, the pharmaceutical landscape of 2025 is fundamentally different. As the industry faces the largest patent cliff in history, the traditional approach to managing mature portfolios is no longer merely outdated—it is a fiscal liability. With mature products currently accounting for 20% to 40% of annual revenue for many top-tier biopharmaceutical companies, the pressure to optimize these assets has become a board-level imperative.
The Looming Patent Cliff and the Need for Radical Rebalancing
The global pharmaceutical industry is currently bracing for a wave of patent expirations that threatens to erase billions in annual revenue. As these primary growth drivers lose exclusivity, companies are scrambling to identify new sources of capital. For many, the answer lies hidden in plain sight: the legacy portfolio.
Historically, pharmaceutical firms have struggled to shift their infrastructure away from the high-octane environment of new drug launches. The organizational DNA that successfully brings a novel therapy to market is often ill-equipped to manage a mature product that requires cost-efficiency and lean operational maintenance. The resulting inefficiencies—bloated SG&A (selling, general, and administrative) expenses and the misallocation of top-tier talent—are eroding margins precisely when they are needed most to fund the next generation of breakthrough innovation.
Chronology: From “Maintenance” to “Optimization”
The evolution of mature brand management has been driven by three distinct phases:
- The Era of Neglect (1990s–2010s): Legacy assets were treated as “cash cows.” Teams were reduced to the bare minimum, and marketing budgets were slashed. The primary goal was to ensure the drug stayed on the shelf until it eventually faded from the market.
- The Era of Operational Inefficiency (2010s–2020): As portfolios grew through M&A, companies found themselves managing vast, disparate sets of products. The legacy infrastructure remained, creating silos and redundant compliance functions that consumed internal resources.
- The Era of Strategic Outsourcing (2025–Present): Companies are now adopting a proactive, outsourced model. By handing off regulatory, safety, and supply chain functions to specialized partners, they are transforming legacy assets into high-efficiency engines of sustainable revenue.
Supporting Data: The Case for a Leaner Model
The argument for outsourcing is not just anecdotal; it is rooted in measurable operational gains.
- Workload Reduction: In a recent case study, a top-20 multinational biopharmaceutical firm utilized an outsourced regulatory services model. By offloading routine lifecycle maintenance, the company reduced its internal regulatory workload by 20% within just 24 months. This allowed their senior staff to pivot toward high-value activities, such as new brand development and clinical pipeline oversight.
- Cost Efficiency: By centralizing operations and reducing the headcount required for legacy maintenance, firms can significantly lower SG&A costs. When outsourced partners use outcome-based, risk-and-reward models, they align their financial interests with the longevity and profitability of the brand.
- Scalability: For a rapidly growing specialty firm managing 10+ brands across six therapeutic areas, the complexity of maintaining local compliance in disparate markets often leads to burnout and oversight errors. Transitioning to a dedicated external partner provides the necessary “boots on the ground” in each region, ensuring compliance with local labeling, safety reporting, and supply chain requirements without the need for expensive cross-border hiring.
Expert Perspectives: Redefining Commercialization
"Drugs that are late in the product life cycle require a very different approach to commercialization than new launches," says Kirsten Jacobs, senior vice president of regulatory, compliance, and pharmacovigilance at Cencora.
Jacobs argues that the traditional, internal-heavy model is fundamentally flawed for older assets. "Marketing costs should go down, since marketing activities aren’t needed to the same extent as just after launch," she notes. "Reducing headcount can lower costs. So can centralizing operations."
Stephan Hütter, director of global client engagement at Cencora, emphasizes that this is not just about cutting costs; it is about protecting the asset’s continuity. "A top-20 multinational biopharmaceutical company wanted to ensure that its mature products would remain available to the patients who needed them," Hütter explains. "But its experienced internal team of regulatory-affairs professionals needed to be freed from routine lifecycle maintenance work… The program had reduced the company’s internal workload by 20% by the end of its second year."
Implications for Global Market Access and Compliance
As pharmaceutical companies look to squeeze every drop of value from mature brands, they face increasing pressure from regulatory bodies, particularly in Europe. Health Technology Assessment (HTA) bodies are now demanding robust evidence of clinical and economic value even for off-patent drugs.
For a firm without a presence in a specific region, this presents a significant hurdle. Outsourcing partners with expertise in biostatistics, policy, and health economics act as a force multiplier. They allow companies to:
- Navigate Regulatory Fragmentation: Manage local labeling and safety reporting in real-time.
- Optimize Market Access: Provide strategic guidance on country-mix and contracting strategies that align with current reimbursement landscapes.
- Ensure Pharmacovigilance: Supply "Responsible Persons" and "Qualified Persons" to meet stringent EU safety requirements, effectively bypassing the need for massive, localized HR infrastructure.
Breathing New Life into Established Brands
Perhaps the most compelling implication of this new model is the potential for "re-ignition." When an internal team is no longer bogged down by the minutiae of regulatory filing and safety reporting, they are free to look at their mature portfolio with a fresh, innovative eye.
Strategic partners can assist in:
- Formulation Innovation: Developing fixed-dose combinations or new delivery mechanisms that address current patient needs.
- Indication Expansion: Repurposing clinical data to identify secondary therapeutic indications, effectively extending the lifecycle of the drug.
- Regional Expansion: Entering under-penetrated markets by leveraging the partner’s existing regulatory and supply chain footprint.
Conclusion: A New Standard for Portfolio ROI
In the current macroeconomic climate, the status quo is the greatest threat to a pharmaceutical company’s longevity. By treating mature assets as a burden to be managed rather than an opportunity to be optimized, companies are leaving revenue on the table and distracting their best people from the next great breakthrough.
Strategic outsourcing represents a paradigm shift. It allows for the marriage of specialized external expertise with internal strategic focus. For the forward-thinking executive, the path forward is clear: reduce the operational burden, leverage global scale, and protect the revenue that sustains the future of innovation. In doing so, companies will find that even the most "mature" assets can continue to deliver growth and, most importantly, provide essential treatments to the patients who rely on them.
Disclaimer: This article is sponsored content. The information provided does not constitute legal advice and may contain marketing statements regarding Cencora. The reader is strongly encouraged to review available information related to the topics discussed in the article and to rely on their own experience and expertise in making decisions related thereto.
